Biotechnology company, Prothena, has announced positive topline Phase 1 SAD study results for PRX005, an investigational tri-epitopic antibody for the treatment of Alzheimer’s disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,